Benjamin Edwards Inc’s Celgene Corp CELG Stock Holding History

Benjamin Edwards Inc’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-200	Closed	-$19K	–	335
2019 Q1	$19K	Buy	+200	New	+$17.5K	0.09%	165

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Benjamin Edwards Inc's CELG Position: Q2 2019 in Review

Benjamin Edwards Inc sold out of Celgene Corp (CELG) in Q2 2019, closing a stake of 200 shares — an estimated $19K sold.

Benjamin Edwards Inc first reported a position in CELG in Q1 2019 and held it in 1 quarter. The position peaked at $19K in Q1 2019. 1,287 funds tracked by Wall St. Rank hold CELG as of Q2 2019.

Benjamin Edwards Inc reported no remaining Celgene Corp position as of Q2 2019 after selling out during the quarter.
Benjamin Edwards Inc sold 200 Celgene Corp shares in Q2 2019, an estimated $19K.
Benjamin Edwards Inc first reported a position in Celgene Corp in Q1 2019 and held it in 1 quarter.
Benjamin Edwards Inc's Celgene Corp position peaked at $19K in Q1 2019.
1,287 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2019.

Based on Benjamin Edwards Inc's 13F filing for Q2 2019, filed 8 Aug 2019.